ADAPTHEALTH CORP.DL-,0001

AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health, spinning out e‑commerce operations and exiting certain drop‑ship supply activities to simplify the company and reallocate resources. The company reported 16% Q2 revenue growth but is addressing higher-than-expected service costs in a new West Coast capitated contract and working with its partner to improve economics. Management plans to prioritize organic growth in sleep and respiratory, reduce leverage to about 2.5x, and pursue targeted tuck-in acquisitions while investing in sleep technology and patient digital tools. » More on finance.yahoo.com

AdaptHealth reported a Q2 loss of $1.07 per share versus an expected $0.15 and revenue of $740.3 million, about $106.5 million below analyst forecasts. The company sharply lowered full-year sales guidance to $2.85–2.89 billion (previously $3.45–3.52 billion) and trimmed adjusted EBITDA to $490–520 million from $680–730 million, while reducing free cash flow targets. Shares fell about 47% during the week following the results and guidance revision, raising concerns about the company’s near-term recovery. » More on finance.yahoo.com

AdaptHealth shares plunged about 22.3% premarket after the company failed to show a convincing return to profitability in Q2/2026. Analysts had expected roughly $0.15–0.18 earnings per share and about $849 million in revenue. Market concerns were heightened by earlier GAAP losses and the planned sale of the diabetes business to Cardinal Health. Investors fear possible downward revisions to the full-year outlook and persistently high personnel costs; the stock traded at $8.41, near its 52-week low. » More on de.investing.com